Here`s Why Syros Pharmaceuticals Got Crushed Today
(WorldNews Business)

What happened Shares of Syros Pharmaceuticals (NASDAQ: SYRS) dropped by as much as 49.1% Monday after the company provided a clinical update on its lead drug candidate. Investors probably couldn`t tell by the press release, which had a rosy takeaway on the news, but just one of 48 evaluable patients taking SY-1425 as a potential stand-alone treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) had a complete response.